Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Topical Benoxinate Anesthetic Abuse Causes Severe Corneal Complications and Delays Healing

1 day ago 21

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

A retrospective cohort study conducted at the Alexandria Ophthalmology Hospital Cornea Clinic in Alexandria, Egypt, has documented the severe clinical manifestations, vision-threatening complications, and marked recovery delays associated with the unsupervised abuse of benoxinate topical ophthalmic anesthetics following superficial corneal trauma. Investigating medical records spanning a five-year period between January 2021 and January 2026, researchers compared patients who instilled benoxinate hydrochloride 0.4 percent eye drops against non-users who sustained comparable superficial ocular surface injuries. The evaluation established that topical anesthetic abuse dramatically elevates the occurrence of destructive tissue degradation, including stromal ring infiltration, extensive corneal melting, and full-thickness corneal perforation. While topical ophthalmic anesthetics remain indispensable agents for short-term diagnostic maneuvers and minor clinical procedures within standard professional ophthalmic settings, their illicit or unmonitored repeated instillation as an over-the-counter analgesic creates severe ocular surface cytotoxicity that impedes native epithelial regeneration, suppresses defensive sensory feedback mechanisms, and precipitates structural ocular failure requiring emergency surgical keratoplasty.

The study cohort comprised 181 eyes evaluated across 147 individual patients presenting with confirmed histories of superficial corneal trauma, encompassing injuries induced by foreign body contamination, sharp mechanical objects, contact lens wear, and ultraviolet radiation exposure. Within this cohort, 84 eyes belonged to patients who reported using topical benoxinate, whereas 97 eyes served as the comparative control group of benoxinate non-users who had not applied anesthetic drops. Demographic and occupational analyses revealed profound differences between the two cohorts. Males accounted for 89.3 percent of the benoxinate user group compared to only 44.3 percent of the non-user cohort, reflecting a statistically significant disparity with a p-value below 0.001. Furthermore, occupational welding predominated among anesthetic abusers, representing 76.2 percent of the benoxinate cohort, in stark contrast to the non-user group where 85.6 percent of patients were non-welders. Correspondingly, the predisposing mechanical and environmental triggers varied; ultraviolet flash exposure resulting in photokeratitis and superficial foreign body extractions were the primary precipitating injuries leading to self-medication in the benoxinate group, while non-users more frequently presented with sharp trauma and contact lens-related abrasions.

Clinical presentations differed markedly between the evaluated cohorts at the time of initial examination, demonstrating significant structural damage to the ocular surface and periocular adnexa among anesthetic abusers. Patients administering topical benoxinate exhibited more than twenty times higher odds of developing active corneal melting compared to non-users, with an odds ratio of 20.87 across a 95 percent confidence interval spanning 2.693 to 161.747. Corneal melting was identified in 15 eyes of the benoxinate user group, representing 17.9 percent of those cases. In addition, anterior chamber hypopyon was documented with six-fold higher odds among benoxinate users, demonstrating an odds ratio of 6.267 and a p-value of 0.002. Manifestations of adnexal hypersensitivity and localized chemical toxicity were also prominent, with eyelid contact dermatitis appearing in 9 eyes of the benoxinate group, reflecting nearly eleven times higher odds than in non-users, evidenced by an odds ratio of 11.520. Slit-lamp examinations further revealed diffuse epithelial punctate erosions, extensive epithelial defects, and marked stromal edema with increased corneal thickness throughout the affected cohort.

A critical morphological finding identified in the retrospective cohort was the distinct configuration of corneal infiltration, specifically the development of stromal ring infiltrates. Ring infiltration occurred exclusively within the benoxinate user cohort, presenting in 26 eyes, or 31.0 percent of the group, while being entirely absent among non-users, yielding a statistically significant difference with a p-value below 0.001. The emergence of dense stromal ring infiltrates in topical anesthetic abuse poses an acute diagnostic challenge for treating clinicians because the clinical picture closely simulates microbial keratitis, particularly parasitic Acanthamoeba infections. The historical misattribution of these sterile or secondarily colonized ring infiltrates often causes diagnostic delays or misdirected antimicrobial regimens. Alongside ring formations, secondary vascularization and full-thickness perforation presented substantial management challenges. Corneal neovascularization, characterized by deep fibrovascular ingrowth penetrating the corneal stroma with associated stromal opacity, was diagnosed in 7 eyes, or 8.3 percent of the benoxinate cohort, while frank corneal perforation occurred in 17 eyes, accounting for 20.2 percent of the group.

The study examined the direct correlations between the frequency of drug administration and the severity of clinical presentations among the 84 eyes within the benoxinate cohort. High frequency of drug use was defined as applying the anesthetic drops more than six times daily, whereas low frequency was categorized as fewer than six daily applications. High-frequency administration was documented in 50 eyes, constituting 59.5 percent of the total user population. Patients in the high-frequency category exhibited markedly increased rates of vision-threatening pathology, including corneal melting in 15 eyes, representing 30.0 percent, and ring infiltration in 26 eyes, representing 52.0 percent, both achieving statistical significance with p-values below 0.001. Crucially, all 17 documented occurrences of full-thickness corneal perforation, representing 34.0 percent of high-frequency cases, occurred solely among high-frequency users, with no perforations observed in the low-frequency group. High-frequency application was also associated with more than four-fold increased odds of developing stromal neovascularization and more than two-fold increased odds of presenting with severe periocular contact dermatitis.

In addition to application frequency, the total duration of anesthetic exposure prior to hospital presentation proved to be a decisive determinant of cumulative corneal damage. Across the benoxinate cohort, the reported duration of use spanned from 2 to 50 days, with a calculated mean exposure duration of 11.67 days and a standard deviation of 9.56 days. Correlation analyses confirmed that longer anesthetic exposure correlated positively and significantly with prolonged total healing time, demonstrating a correlation coefficient of r equals 0.411 and a p-value of 0.001. Conversely, prolonged duration exhibited moderate, statistically significant negative correlations with final visual outcomes. Increased duration of use was negatively correlated with post-treatment best-corrected visual acuity, exhibiting a correlation coefficient of r equals negative 0.481 with a p-value below 0.001, as well as with the absolute magnitude of visual acuity improvement, showing a correlation coefficient of r equals negative 0.490 and a p-value below 0.001.

A critical behavioral and management challenge highlighted by the investigation was the continuation of benoxinate use even after formal ophthalmic presentation and initiation of treatment. Out of 61 eyes in the user group that completed clinical follow-up, 31 eyes, or 50.8 percent, belonged to patients who persisted in applying benoxinate eye drops contrary to urgent medical instructions to discontinue them. Non-compliance produced severe downstream structural sequelae: eyelid contact dermatitis was documented in 6 eyes, representing 19.4 percent, and ring infiltration in 19 eyes, representing 61.3 percent of the continuing subpopulation. Furthermore, destructive tissue complications developed exclusively within this non-compliant group. Active corneal melting occurred in 12 eyes, corneal vascularization in 7 eyes, and full-thickness perforation in 15 eyes, representing 48.4 percent of those who continued drops. Ultimately, adherent leukoma—a severe, vascularized leucomatous corneal scar integrated with anterior synechiae—manifested solely among patients who persisted in using the drops during therapy, affecting 15 eyes, or 48.4 percent, with a p-value below 0.001.

The evaluation of visual recovery and tissue resolution demonstrated marked differences between topical anesthetic abusers and non-users. Best-corrected visual acuity was recorded as decimal fractions across follow-up, with non-numerical outcomes such as counting fingers and light perception converted into standardized decimal values via the Freiburg Visual Acuity Test and corresponding logMAR definitions. Although both study groups demonstrated gains in visual acuity following treatment, the magnitude of improvement was significantly lower among benoxinate users. The mean improvement in decimal visual acuity was 0.18 with a standard deviation of 0.25 in the benoxinate cohort, compared to an improvement of 0.34 with a standard deviation of 0.23 in the non-user cohort, demonstrating a statistically significant divergence with a p-value below 0.001. Similarly, the mean healing duration required for epithelial defect closure was drastically protracted in the benoxinate group, averaging 41.05 days across a range of 4 to 100 days, compared to a mean of 7.93 days across a range of 3 to 21 days in non-users, representing a large statistical effect size with a correlation coefficient of r equals 0.645.

The clinical management of benoxinate toxicity required aggressive, multimodal medical interventions structured around immediate drug discontinuation, ocular surface support, and surgical rescue for perforated eyes. Standardized medical management implemented by cornea specialists included the immediate cessation of the offending topical anesthetic, broad-spectrum topical moxifloxacin therapy, intensive lubrication with preservative-free artificial tears, and systemic analgesics. Supportive systemic treatments, including doxycycline and oral ascorbic acid, were prescribed to arrest progressive matrix degradation in cases displaying active corneal melting. Sterile refractory ulcerations were managed using autologous serum eye drops and therapeutic bandage contact lenses, while eyelid contact dermatitis was treated with combined antibiotic and corticosteroid ointments. Eyes presenting with secondary microbial keratitis underwent prompt corneal scrapings for microbiological culture and sensitivity testing before empiric antibiotic initiation. When stromal dissolution progressed to corneal melting or perforation, patients were referred for emergency corneal grafting to preserve ocular anatomical integrity.

The researchers contextualized their findings within the existing body of ophthalmic literature while identifying important methodological limitations that govern the interpretation of their retrospective data. The high proportion of male welders vulnerable to anesthetic abuse aligns with prior international reports by Sharifi, Attar, and Yagci, which highlighted occupational ultraviolet arc exposure as a frequent initiator of debilitating corneal pain driving individuals to seek unprescribed drops. Mechanistically, topical anesthetics exert documented dose- and time-dependent cytotoxic effects on corneal epithelial cells, suppressing cell migration, blunting normal blink reflexes, disrupting the tear film, and accelerating stromal necrosis. However, the study’s retrospective design introduced substantial differential attrition, as 23 eyes in the benoxinate cohort were lost to follow-up compared to only 2 eyes in the control group. This differential loss of 27 percent versus 2 percent introduces potential attrition bias that may influence effect size calculations, while long-term post-keratoplasty complications such as delayed epithelialization, secondary ocular hypertension, and graft rejection warrant systematic prospective evaluation.

Subject of Research: Clinical presentations, complications, and visual outcomes associated with topical benoxinate abuse following superficial corneal trauma

Article Title: Clinical presentations, complications, and outcomes of benoxinate topical ophthalmic anesthetic abuse: a retrospective cohort study

Article References: Sakr, S. I., Nayel, A. A., ElHennawi, D. H., Saad, F. I., & Ghaith, A. A. (2026). Clinical presentations, complications, and outcomes of benoxinate topical ophthalmic anesthetic abuse: a retrospective cohort study. Journal of Ophthalmic Inflammation and Infection, 16(1), Article 64. https://doi.org/10.1186/s12348-026-00636-4

Image Credits: AI Generated

DOI: 10.1186/s12348-026-00636-4

Keywords: benoxinate hydrochloride, topical ophthalmic anesthetics, corneal trauma, corneal melting, corneal perforation, ring infiltration, toxic keratopathy, ocular surface toxicity, welders, ultraviolet photokeratitis, contact dermatitis, adherent leukoma, retrospective cohort study, best-corrected visual acuity, corneal neovascularization, Alexandria Ophthalmology Hospital

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway